Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 3801–3850 of 75328
Effective June 5, 2025, the Company's Chair, John S. Moody, retired as Chair of the Board and Douglas B. Hansen assumed the position of the Company's Chair of the Board.
On June 5, 2025, the Board of Directors appointed Jeanette M. Bjorkquist to serve as the Company’s principal financial officer in addition to her role as principal accounting officer.
Ms. Bjorkquist succeeds Jason A. Okazaki, who previously served as both the Company’s principal executive officer and principal financial officer.
Effective June 6, 2025, the Board of Directors (the “Board”) of the Company increased the number of directors to five and appointed Messrs. Shawn Canter and Aron Schwartz to serve as members of the board of directors of the Company.
Effective June 6, 2025, the Board of Directors (the “Board”) of the Company increased the number of directors to five and appointed Messrs. Shawn Canter and Aron Schwartz to serve as members of the board of directors of the Company.
Effective as of the Separation Date, the Board appointed Tammy Furlong, age 54, the Company’s Chief Financial Officer and Principal Financial and Accounting Officer, to succeed Mr. Ferra as President and Interim Chief Executive Officer
In connection with the Merger, the Company terminated the employment of Joseph J. Ferra, Jr., as the Company’s President, Chief Executive Officer, effective as of June 30, 2025
On June 8, 2025, Dr. Alan J. Tuchman resigned as Chief Executive Officer and director of the Company, effective June 8, 2025. Dr. Tuchman will serve as Chief Medical Officer of the Company.
On June 4, 2025, Dr. Daniel L. Alkon resigned as an officer, director and Chief Science Officer of the Company to become a consultant working with the Company’s newly established Bryostatin Development Committee
On June 6, 2025, Mr. Joshua Silverman was appointed as Executive Chairman of the Company’s board of directors and in consideration of his new role, Mr. Silverman will be paid a monthly salary of $30,000 per month.
Mr. Moss will serve as a Class I Director, with a term expiring at the Company's 2025 annual meeting of stockholders and will serve on the Nominating and Corporate Governance Committee of the Board.
Mr. Roberts will serve as a Class III Director, with a term expiring at the Company’s 2027 annual meeting of stockholders and will serve on the Audit and Risk Committee and the Compensation Committee of the Board.
On June 9, 2025, International Flavors & Fragrances Inc. (the “Company”) announced that Ms. Virginia Drosos has been appointed to its board of directors (the “Board”), effective June 16, 2025 (the “Effective Date”).
the Board increased the size of the Board by one to a total of eight Directors and appointed Corning Painter as a Director, effective immediately.
Ken Moelis, who has served as Chief Executive Officer of the Company since the Company’s inception in 2007, will become Executive Chairman.
Jeff Raich, Co-Founder and Co-President, has been appointed Executive Vice Chairman of Moelis and will continue to lead key business areas of the Firm.
Navid Mahmoodzadegan, Co-Founder and Co-President, will succeed Mr. Moelis as Chief Executive Officer and will also join the Board of Directors of the Company.
Mr. Martin resigned from the Board
Mr. Brust was appointed as a member of the Board
Scott Behrens will cease to serve as Executive Vice President, Chief Financial Officer and Chief Accounting Officer of the Company effective July 1, 2025.
On June 9, 2025, ACI Worldwide, Inc. (the “Company”) announced the appointment of Robert Leibrock as its Chief Financial Officer and Chief Accounting Officer effective July 1, 2025.
On June 4, 2025, General Dynamics Corporation (the “company”) announced that Danny Deep, currently executive vice president, Combat Systems, has been promoted to executive vice president, Global Operations.
On June 9, 2025, Symbotic Inc. (the “Company”) announced the appointment of Izilda “Izzy” Martins as Chief Financial Officer and principal financial officer of the Company, effective August 9, 2025.
on June 9, 2025, the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) increased the authorized size of the Board from seven directors to eight directors and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Mark Bachleda, Pharm.D., M.B.A., to the Board as a Class I director.
Richard Matricaria, formerly the Company’s Chief Operating Officer, Western Division, was named Senior Vice President and Chief Growth Officer effective May 1, 2025.
Randy Breaux will be retiring as Group President, GPC North America, effective as of August 1, 2025
the Board of Directors of the Company has appointed Alain Masse to the newly created position of President, North American Automotive, effective as of the Effective Date.
On June 5, 2025, the Board of Directors (the “Board”) of biote Corp. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee, appointed Richard R. Barrera to serve as a member of the Board to fill the vacancy created by the prior resignation of Steven J. Heyer
vacancy created by the prior resignation of Steven J. Heyer
On June 5, 2025, Preston Grasty notified KinderCare Learning Companies, Inc. (the “Company”) that he would be resigning from the Company’s Board of Directors (the “Board”), effective immediately.
Jason C. Murgio was appointed by the Class B Majority Shareholder (as defined below) to the Board to serve as a Designated Director (as defined below).
T. Andrew Smith, Jonathan A. Carnella, Gregory A. Samay and Kendall K. Young each resigned from the Company’s board of directors effective as of the Effective Time.
T. Andrew Smith, Jonathan A. Carnella, Gregory A. Samay and Kendall K. Young each resigned from the Company’s board of directors effective as of the Effective Time.
the following officers resigned from the offices indicated besides such officers’ names and ceased to serve in such offices: Kendall K. Young Chief Executive Officer and President Nicholas R. Balzo Chief Financial Officer and Treasurer Ann B. Harrington General Counsel and Secretary
the following officers resigned from the offices indicated besides such officers’ names and ceased to serve in such offices: Kendall K. Young Chief Executive Officer and President Nicholas R. Balzo Chief Financial Officer and Treasurer Ann B. Harrington General Counsel and Secretary
T. Andrew Smith, Jonathan A. Carnella, Gregory A. Samay and Kendall K. Young each resigned from the Company’s board of directors effective as of the Effective Time.
T. Andrew Smith, Jonathan A. Carnella, Gregory A. Samay and Kendall K. Young each resigned from the Company’s board of directors effective as of the Effective Time.
the following officers resigned from the offices indicated besides such officers’ names and ceased to serve in such offices: Kendall K. Young Chief Executive Officer and President Nicholas R. Balzo Chief Financial Officer and Treasurer Ann B. Harrington General Counsel and Secretary
On June 3, 2025, the Board of Directors of Applied Energetics expanded its number to seven members and appointed Christopher Donaghey and Scott Andrews to serve as new directors., effective immediately.
On June 3, 2025, the Board of Directors of Applied Energetics expanded its number to seven members and appointed Christopher Donaghey and Scott Andrews to serve as new directors., effective immediately.
On June 5, 2025, the Board of Directors (the “ Board ”) of the Company, with the recommendation of the Nominating and Corporate Governance Committee, appointed Ms. Saundra Pelletier as a member of the Board.
On and effective June 5, 2025, the Board of Directors of First Western Financial, Inc. (the “Company”) appointed Matthew C. Cassell to serve as Chief Revenue Officer of First Western Trust Bank (the “Bank”).
on June 7, 2025, Mr. Burns notified the Trust and the Board of his intent to resign as a director of the Company, effective June 7, 2025.
the Board appointed Raffiq Nathoo as an independent director, effective immediately
On June 5, 2025, Daniel S. Devorsetz stepped down as Chief Investment Officer and Chief Operating Officer of Horizon Technology Finance Corporation (the “ Company ”.
On June 5, 2025, the Board of Directors of the Company unanimously elected Paul G. Seitz, 38, as Chief Investment Officer.
On June 5, 2025, Daniel S. Devorsetz stepped down as Chief Investment Officer and Chief Operating Officer of Horizon Technology Finance Corporation (the “ Company ”.
Raymond Kelly has been appointed to the Board of Directors of the Company and the Bank, effective June 6, 2025.
On June 9, 2025, FibroBiologics, Inc. (the “Company”) announced that Jason D. Davis has been appointed as the Company’s Chief Financial Officer, effective as of June 9, 2025 (the “Effective Date”).
On June 3, 2025, the Board of Directors of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), approved the appointment of Dr. Kaouthar Lbiati, a director of the Company, as interim Chief Executive Officer, effective June 16, 2025.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.